Evidence map›Paper›PMID 39121016›Full record

ReviewProtein & cell2025

Advances in gene and cellular therapeutic approaches for Huntington's disease.

Xuejiao Piao, Dan Li, Hui Liu, Qing Guo, Yang Yu

Erratum issuedAbstract readReview
In one paragraph

Review in Protein & cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Xuejiao PiaoClinical Stem Cell Research Center, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0002-1671-242X
Dan LiClinical Stem Cell Research Center, Peking University Third Hospital, Beijing 100191, China.
Hui LiuClinical Stem Cell Research Center, Peking University Third Hospital, Beijing 100191, China.
Qing GuoClinical Stem Cell Research Center, Peking University Third Hospital, Beijing 100191, China.
Yang YuClinical Stem Cell Research Center, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0002-4310-1966

Funding

CAMS Innovation Fund for Medical Sciences HH22KYZX000National Key R&D Program of China 2021YFC2700303National Natural Science Foundation of China 82192873National Natural Science Foundation of China 82225019
6 · The paper itself

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disorder caused by the abnormal expansion of CAG trinucleotide repeats in the Huntingtin gene (HTT) located on chromosome 4. It is transmitted in an autosomal dominant manner and is characterized by motor dysfunction, cognitive decline, and emotional disturbances. To date, there are no curative treatments for HD have been developed; current therapeutic approaches focus on symptom relief and comprehensive care through coordinated pharmacological and nonpharmacological methods to manage the diverse phenotypes of the disease. International clinical guidelines for the treatment of HD are continually being revised in an effort to enhance care within a multidisciplinary framework. Additionally, innovative gene and cell therapy strategies are being actively researched and developed to address the complexities of the disorder and improve treatment outcomes. This review endeavours to elucidate the current and emerging gene and cell therapy strategies for HD, offering a detailed insight into the complexities of the disorder and looking forward to future treatment paradigms. Considering the complexity of the underlying mechanisms driving HD, a synergistic treatment strategy that integrates various factors-such as distinct cell types, epigenetic patterns, genetic components, and methods to improve the cerebral microenvironment-may significantly enhance therapeutic outcomes. In the future, we eagerly anticipate ongoing innovations in interdisciplinary research that will bring profound advancements and refinements in the treatment of HD.

Indexed as

Cell- and Tissue-Based TherapyGenetic TherapyHuntington DiseaseAnimalsHumansHuntingtin ProteinHTT protein, humanHuntingtin Proteincell therapygene therapyHuntingtin gene (HTT)Huntington’s disease (HD)interdisciplinary research

Identifiers

PMID39121016
PMCPMC12120246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.